Moleculin Biotech is expected to report a Q2 2026 loss of $1.55 per share on zero revenue, with the current stock price of $4.85 trading significantly below the $15.00 average analyst price target. Investors are primarily focused on clinical trial updates for the company’s lead drug candidate, Annamycin, and its progress toward Phase 3 trials for Acute Myeloid Leukemia.
Management is expected to provide commentary on the recent Fast Track Designation and the durability of patient responses observed in the current Phase 1/2 studies. The company's cash runway and R&D spending efficiency remain critical as it approaches potentially pivotal clinical milestones in the second half of 2026.